Table 1 Main characteristics of the trials included in the meta-analysis
Study | Type of study | Included population | Drug tested | concomitant antibacterial agents | Enrolled patients | Intention to treat | Jadad score | |
|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | Ertapenem | Piperacillin/tazobactm | Â | Â | Â | Â |
Dela Pena et al. | Multicentre open-label RCT | Hospitalized adults, ≥18 years-old, with cIAIs that extended beyond the wall of a hollow organ | Ertapenem 1 g once daily, i.v.(possible change to i.m. after 2 days of therapy) | Piperacillin/tazobactm 3.375 g i.v. q6h or 4.5 g i.v. q8h | Vancomycin or teicoplanin, for resistant Gram-positive pathogens | 399 | 180vs190 | 3 |
Namias et al. | Multicentre double-blind RCT | Hospitalized adults,18-90 years-old, with presumptive or confirmed cIAIs | Ertapenem 1 g once daily, i.v., followed by a placebo every 6 h for three additional doses daily | Piperacillin/tazobactm 3.375 g i.v. q6h | Vancomycin if MRSA or enterococci isolated | 500 | 247vs247 | 5 |
Roy et al. | Multicentre double-blind RCT | Females ≥16 years-old, With APIs, required ≥3 days of parenteral antimicrobial therapy | Ertapenem 1 g once daily, i.v., followed by a placebo every 6 h for three additional doses daily | Piperacillin/tazobactam 3.375 g i.v. q6h (adjusted in case of low creatinine clearance). | Vancomycin for resistant Gram-positive organisms, antifungals | 450 | 216vs196 | 5 |
Solomkin et al. | Multicentre double-blind RCT | Hospitalized adults ≥18 years-old, with confirmed cIAIs | Ertapenem 1 g once daily, i.v., followed by a placebo every 6 h for three additional doses daily | Piperacillin/tazobactam 3.375 g i.v. q6h (adjusted for renal failure) | Vancomycin against enterococci or MRSA | 633 | 323vs310 | 5 |
Graham et al. | Multicentre double-blind RCT | adults ≥18 years-old, with CSSSIs, required parenteral antimicrobial therapy | Ertapenem 1 g once daily, i.v., followed by a placebo every 6 h for three additional doses daily | Piperacillin/tazobactam 3.375 g i.v. q6h | Not permitted | 540 | 274vs266 | 4 |
Lipsky et al. | Multicentre double-blind RCT | diabetes mellitus adult patients, with a foot infection that did not extend above the knee | Ertapenem 1 g once daily, i.v., followed by a placebo every 6 h for three additional doses daily | Piperacillin/tazobactam 3.375 g i.v. q6h | Vancomycin against enterococci or MRSA | 639 | 295vs291 | 5 |